To assess the efficacy of oral cannabis extract for pain management in cancer patients undergoing cancer directed treatment

Pilot Study to assess the efficacy of cannabinoid-rich Oral cannabis extract for pain management in cancer patients undergoing cancer directed treatment (surgery, systemic therapy, radiation therapy)and who have received systemic analgesics - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068682

Enrollment

Registered

2024-06-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C801- Malignant (primary) neoplasm, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients Histopathologically confirmed cancer diagnosis Moderate or severe pain Stable regime of pain management inclusive of NSAIDS weak opioid opioids Palliative intent therapy

Exclusion criteria

Exclusion criteria: Major psychiatric disorder Cardiovascular disorder Epilepsy Significant renal or hepatic impairment Pregnancy Lactating Women Patients who were currently using or had used cannabinoid based medications within 30 days of study entry

Design outcomes

Primary

Measure	Time frame
Improvement in pain relief Using baseline assessment measures gathered at visit 0 Screening assessments collected at visits 1 to 5 and follow up will be used to determine whether the administration of cannabinoid rich oral cannabis extract will improve pain relief in individuals with chronic pain Assessments will be made using a visual analogue scaleTimepoint: 90 Days	—

Secondary

Measure	Time frame
Quality of lifeTimepoint: Baseline 30 days 60 days 90 days	—

Countries

India

Contacts

Public ContactDr Manish Singhal

Indraprastha Apollo Hospitals New Delhi

singhaloncocare@yahoo.co.in9818521155

Outcome results